Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Evaluation of the HIV-infected patient with hepatobiliary complaints

C Mel Wilcox, MD
Section Editor
John G Bartlett, MD
Deputy Editor
Jennifer Mitty, MD, MPH


The era of potent antiretroviral therapy (ART) has been associated with a marked decrease in morbidity and mortality in HIV-infected patients.

However, those who present with advanced immunosuppression are at risk for a wide variety of opportunistic infections (OIs), such as Cryptosporidium, Isospora, Microsporidium, Mycobacterium avium complex (MAC), and cytomegalovirus (CMV) and hepatobiliary complications, such as acalculous cholecystitis and AIDS-related cholangiopathy [1]. Those patients who undergo therapy are also at risk for treatment-related adverse events, such as lactic acidosis, hepatic steatosis, and drug-induced hepatotoxicity. Finally, a significant proportion of patients are infected with hepatitis B and/or C virus, due to shared routes of transmission.

This topic will discuss a guided approach to the evaluation of the HIV-infected patient with hepatobiliary complaints. More detailed information regarding viral hepatitis B and hepatitis C infections and AIDS cholangiopathy are found elsewhere. (See "Evaluation of the HIV-infected patient with chronic hepatitis C virus infection" and "Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient" and "AIDS cholangiopathy".)


Chronic viral hepatitis — The most common cause of hepatomegaly in HIV-infected patients is chronic viral hepatitis with either hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infections [2]. End-stage liver disease is a major cause for inpatient admissions and mortality in the era of antiretroviral therapy (ART) [3,4]. In patients with chronic HBV or HCV infection, concomitant HIV infection is associated with higher rates of morbidity and mortality related to liver disease. (See "Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient" and "Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient".)

Depending on the risk group studied, it is estimated that approximately 30 to 80 percent of patients with HIV have concomitant hepatitis C and approximately 5 to 10 percent have chronic hepatitis B. There are few data on the seroprevalence of multiple hepatitides, such as hepatitis B and C combined; one study of 423 HIV-infected patients in Spain found that approximately 5 percent of patients had HBV, HCV, and delta virus infections [5] The most common risk factor for acquisition of HCV is injection drug use, while HBV can be acquired both sexually and parenterally. However, there are emerging data on acute HCV infection among men who have sex with men (MSM) who report sex with trauma or in association with other genital ulcer disease [6,7].


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Jul 6, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Keaveny AP, Karasik MS. Hepatobiliary and pancreatic infections in AIDS: Part II. AIDS Patient Care STDS 1998; 12:451.
  2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (Accessed on January 28, 2016).
  3. Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632.
  4. Lumbreras B, Jarrín I, del Amo J, et al. Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: differences before and after HAART. AIDS 2006; 20:111.
  5. Arribas JR, González-García JJ, Lorenzo A, et al. Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain. AIDS 2005; 19:1361.
  6. Danta M, Brown D, Bhagani S, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007; 21:983.
  7. Götz HM, van Doornum G, Niesters HG, et al. A cluster of acute hepatitis C virus infection among men who have sex with men--results from contact tracing and public health implications. AIDS 2005; 19:969.
  8. Ioannou GN, Bryson CL, Weiss NS, et al. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology 2013; 57:249.
  9. Bräu N, Salvatore M, Ríos-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44:47.
  10. Madejón A, Vispo E, Bottecchia M, et al. Lack of hepatitis E virus infection in HIV patients with advanced immunodeficiency or idiopathic liver enzyme elevations. J Viral Hepat 2009; 16:895.
  11. Dalton HR, Bendall RP, Keane FE, et al. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med 2009; 361:1025.
  12. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59.
  13. Saab S, Rickman LS, Lyche KD. Ascites and the acquired immunodeficiency syndrome. Report of 54 cases. Medicine (Baltimore) 1996; 75:131.
  14. Poblete RB, Rodriguez K, Foust RT, et al. Pneumocystis carinii hepatitis in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989; 110:737.
  15. Poles MA, Dieterich DT, Schwarz ED, et al. Liver biopsy findings in 501 patients infected with human immunodeficiency virus (HIV). J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11:170.
  16. Lebovics E, Thung SN, Schaffner F, Radensky PW. The liver in the acquired immunodeficiency syndrome: a clinical and histologic study. Hepatology 1985; 5:293.
  17. Gaslightwala I, Bini EJ. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol 2006; 44:1026.
  18. Rafiq N, Stepanova M, Lam B, et al. Predictors of chronic liver disease in individuals with human immunodeficiency virus infection. Ann Hepatol 2013; 13:60.
  19. McGovern BH, Ditelberg JS, Taylor LE, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 2006; 43:365.
  20. Brown TT, Mehta SH, Sutcliffe C, et al. Hepatic steatosis associated with increased central body fat by dual-energy X-ray absorptiometry and uncontrolled HIV in HIV/hepatitis C co-infected persons. AIDS 2010; 24:811.
  21. Nishijima T, Gatanaga H, Shimbo T, et al. Traditional but not HIV-related factors are associated with nonalcoholic fatty liver disease in Asian patients with HIV-1 infection. PLoS One 2014; 9:e87596.
  22. Price JC, Seaberg EC, Latanich R, et al. Risk factors for fatty liver in the Multicenter AIDS Cohort Study. Am J Gastroenterol 2014; 109:695.
  23. Woreta TA, Sutcliffe CG, Mehta SH, et al. Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology 2011; 140:809.
  24. McGovern BH. Hepatic steatosis in HIV/HCV-coinfected patients: time to reevaluate! Gastroenterology 2011; 140:772.
  25. Sterling RK, Contos MJ, Smith PG, et al. Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 2008; 47:1118.
  26. Soriano V, Puoti M, Garcia-Gascó P, et al. Antiretroviral drugs and liver injury. AIDS 2008; 22:1.
  27. Norris W, Paredes AH, Lewis JH. Drug-induced liver injury in 2007. Curr Opin Gastroenterol 2008; 24:287.
  28. De Angelis C, Mangone M, Bianchi M, et al. An update on AIDS-related cholangiopathy. Minerva Gastroenterol Dietol 2009; 55:79.
  29. Rakotondravelo S, Poinsignon Y, Borsa-Lebas F, et al. Complicated atazanavir-associated cholelithiasis: a report of 14 cases. Clin Infect Dis 2012; 55:1270.
  30. Schneiderman DJ, Arenson DM, Cello JP, et al. Hepatic disease in patients with the acquired immune deficiency syndrome (AIDS). Hepatology 1987; 7:925.
  31. Benson CA. Disease due to the Mycobacterium avium complex in patients with AIDS: epidemiology and clinical syndrome. Clin Infect Dis 1994; 18 Suppl 3:S218.
  32. Busti AJ, Hall RG, Margolis DM. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy 2004; 24:1732.
  33. Zucker SD, Qin X, Rouster SD, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci U S A 2001; 98:12671.
  34. Teare JP, Daly CA, Rodgers C, et al. Pancreatic abnormalities and AIDS related sclerosing cholangitis. Genitourin Med 1997; 73:271.
  35. Bilgin M, Balci NC, Erdogan A, et al. Hepatobiliary and pancreatic MRI and MRCP findings in patients with HIV infection. AJR Am J Roentgenol 2008; 191:228.
  36. Keaveny AP, Karasik MS. Hepatobiliary and pancreatic infections in AIDS: Part one. AIDS Patient Care STDS 1998; 12:347.